In high-risk patients with diabetes in a contemporary healthcare system, “significant gaps” remain in the use of guideline-directed statin intensity (GDSI) for primary prevention, a
A 1.5 million-participant study of incident cardiovascular disease shows that more than one-half of cases and about one-fifth of related deaths result from 5 modifiable
In a phase 1 pharmacokinetics and pharmacodynamics trial, muvalaplin was safe and well-tolerated and lowered lipoprotein(a) (Lp[a]) levels up to 65% after 14 days of daily
Compared with placebo in people with HIV infection, pitavastatin decreased the risk of major adverse cardiovascular events over a median follow-up of 5.1 years, researchers
Atorvastatin reduced the incidence of cardiac dysfunction among patients with lymphoma treated with anthracycline-based chemotherapy in the STOP-CA (Statins to Prevent the Cardiotoxicity of Anthracyclines)
A nationwide study from Denmark shows a greater LDL cholesterol response for adults aged 75 years or older to low- to moderate-intensity statins than in
Among participants in the National Health and Nutrition Examination Survey for 2015–20, variations in guideline-recommended statin use among minoritized racial/ethnic groups and women “are not
Current recommendations for screening and managing elevated lipoprotein(a), or Lp(a), are described in a review article with emphasis on the effects of currently available and
In an updated statement, the U.S. Preventive Services Task Force (USPSTF) finds insufficient evidence to assess the balance of benefits and harms of routine screening
In the CLEAR Outcomes (Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen) trial, bempedoic acid was more effective than placebo for primary prevention of major
